Iranian currency rates for December 26

BAKU, Azerbaijan, December 26. The Central Bank of Iran (CBI) announced an official rate of foreign currencies on December 26, Trend reports referring to CBI.

According to the currency exchange rate of the Central Bank of Iran, 8 currencies increased and 21 have decreased in price, compared to December 25.

According to CBI, $1 equals 42,000 Iranian rials and 1 euro equals 44,592 rials.

Currency Iranian rial on December 26 Iranian rial on December 25
1 US dollar USD 42,000 42,000
1 British pound GBP 50,626 50,619
1 Swiss franc CHF 44,995 45,013
1 Swedish krona SEK 3,988 3,989
1 Norwegian krone NOK 4,231 4,242
1 Danish krone DKK 5,995 5,996
1 Indian rupee INR 508 509
1 UAE dirham AED 11,437 11,437
1 Kuwaiti dinar KWD 136,635 136,736
100 Pakistani rupees PKR 18,619 18,620
100 Japanese yens JPY 31,635 31,636
1 Hong Kong dollar HKD 5,382 5,381
1 Omani rial OMR 109,091 109,111
1 Canadian dollar CAD 30,898 30,876
1 New Zealand dollar NZD 26,427 26,443
1 South African rand ZAR 2,464 2,472
1 Turkish lira TRY 2,251 2,251
1 Russian ruble RUB 608 608
1 Qatari riyal QAR 11,539 11,539
100 Iraq dinars IQD 2,878 2,878
1 Syrian pound SYP 17 17
1 Australian dollar AUD 28,161 28,173
1 Saudi riyal SAR 11,201 11,201
1 Bahraini dinar BHD 111,704 111,703
1 Singapore dollar SGD 31,059 31,076
100 Bangladeshi takas BDT 39,494 39,494
10 Sri Lankan rupees LKR 1,149 1,149
1 Myanmar kyat MMK 21 21
100 Nepalese rupees NPR 31,694 31,740
1 Libyan dinar LYD 8,732 8,727
1 Chinese yuan CNY 6,012 6,011
100 Thai baths THB 120,670 120,721
1 Malaysian ringgit MYR 9,493 9,493
1,000 South Korean wons KRW 32,807 32,825
1 Jordanian dinar JOD 59,239 59,239
1 euro EUR 44,592 44,778
100 Kazakh tenge KZT 9,102 9,097
1 Georgian lari GEL 15,624 15,626
1,000 Indonesian rupiahs IDR 2,694 2,694
1 Afghan afghani AFN 475 478
1 Belarus ruble BYN 16,634 16,635
1 Azerbaijani manat AZN 24,707 24,707
100 Philippine pesos PHP 76,026 76,038
1 Tajik somoni TJS 4,117 4,117
1 Turkmen manat TMT 11,975 11,984

In Iran, the official exchange rate is used for the import of some essential products.

SANA system is a system introduced by the Central Bank of Iran to the currency exchange offices, where the price of 1 euro is 324,500 rials, and the price of $1 is 305,639 rials.

NIMA is a system intended for the sale of a certain percentage of the foreign currency gained from export.

The price of 1 euro in this system is 311,151 rials, and the price of $1 is 293,065 rials.

On the black market, $1 is worth about 407,000-410,000 rials, while 1 euro is worth about 432,000-435,000 rials.

 

 

Source: TREND News Agency

 

Azerbaijani currency rates for December 26

BAKU, Azerbaijan, December 26. The official exchange rate of the US dollar and euro against Azerbaijani manat as of December 26, 2022, is set at 1.7 and 1,8068 manat, respectively, Trend reports via Central Bank of Azerbaijan (CBA).

The manat rate to other global currencies for Monday according to the CBA:

Currencies
1 US dollar USD 1,7
1 Euro EUR 1,8068
1 Australian dollar AUD 1,1416
1 Argentine peso ARS 0,0097
1 Belarus ruble BYN 0,6734
1 Brazil real BRL 0,3294
1 UAE dirham AED 0,4629
1 South African rand ZAR 0,0999
100 South Korean won KRW 0,1333
1 Czech koruna CZK 0,0746
1 Chilean peso CLP 0,1939
1 Chinese yuan CNY 0,2437
1 Danish krone DKK 0,2429
1 Georgian lari GEL 0,6311
1 Hong Kong dollar HKD 0,2178
1 Indian rupee INR 0,0205
1 British pound GBP 2,0522
100 Indonesian rupiah IDR 0,0109
100 Iranian rials IRR 0,004
1 Swedish krona SEK 0,1617
1 Swiss franc CHF 1,8216
1 Israeli shekel ILS 0,485
1 Canadian dollar CAD 1,2501
1 Kuwaiti dinar KWD 5,5519
1 Kazakh tenge KZT 0,0037
1 Kyrgyz som KGS 0,0199
100 Lebanese pound LBP 0,112
1 Malaysian ringgit MYR 0,3842
1 Mexican peso MXN 0,0878
1 Moldovan leu MDL 0,0885
1 Egyptian pound EGP 0,0687
1 Norwegian krone NOK 0,1724
100 Uzbek soum UZS 0,0151
1 Polish zloty PLN 0,3892
1 Russian ruble RUB 0,0246
1 Singapore dollar SGD 1,2574
1 Saudi riyal SAR 0,4521
1 SDR (Special Drawing Rights of IMF) XDR 2,2624
1 Turkish lira TRY 0,0911
1 Taiwan dollar TWD 0,0554
1 Tajik somoni TJS 0,1661
1 New Turkmen manat TMT 0,4857
1 Ukrainian hryvnia UAH 0,046
100 Japanese yen JPY 1,2823
1 New Zealand dollar NZD 1,0682

 

 

Source: TREND News Agency

China to End Quarantine on Arrival in Fresh COVID Rule Relaxation

China said Monday it would scrap mandatory quarantine on arrival, further unwinding years of strict virus controls as the country battles a surge in cases.

Having mostly cut itself off from the rest of the world during the pandemic, China is now experiencing an unprecedented surge in infections after abruptly lifting restrictions that torpedoed the economy and sparked nationwide protests.

And in a sudden end to nearly three years of strict border controls, Beijing said late Monday it would scrap mandatory quarantines for overseas travelers.

Since March 2020, all passengers arriving in China have had to undergo mandatory centralized quarantine. This decreased from three weeks to one week this summer, and to five days last month.

But under new rules that will take effect January 8, when COVID-19 will be downgraded to a Class B infectious disease from Class A, they will no longer need to.

“According to the national health quarantine law, infectious disease quarantine measures will no longer be taken against inbound travelers and goods,” the National Health Commission (NHC) said.

The move is likely to be greeted with joy from Chinese citizens and diaspora unable to return and see relatives for much of the pandemic.

But it comes as China faces a wave of cases that studies have estimated could kill around one million people over the next few months.

Many are now grappling with shortages of medicine, while emergency medical facilities are strained by an influx of undervaccinated elderly patients.

“At present, COVID-19 prevention and control in China are facing a new situation and new tasks,” President Xi Jinping said in a directive Monday, according to state broadcaster CCTV.

“We should launch the patriotic health campaign in a more targeted way… fortify a community line of defense for epidemic prevention and control, and effectively protect people’s lives, safety and health,” he said.

‘Impossible’ to track

Hospitals and crematoriums across the country have been overflowing with COVID patients and victims, while the NHC on Sunday announced it would stop publishing daily nationwide infection and death statistics.

That decision followed concerns that the country’s wave of infections is not being accurately reflected in official statistics.

Beijing has admitted the scale of the outbreak has become “impossible” to track following the end of mandatory mass testing.

And last week, the government narrowed the criteria by which COVID-19 fatalities were counted — a move experts said would suppress the number of deaths attributable to the virus.

The winter surge comes ahead of two major public holidays next month, in which millions of people are expected to travel to their hometowns to reunite with relatives.

Authorities are expecting the virus to hit under-resourced rural areas hard, and on Monday called for the guaranteed supply of drugs and medical treatment during New Year’s Day and late January’s week-long Lunar New Year holiday.

In recent days, health officials in the wealthy coastal province Zhejiang estimated that one million residents were being infected per day.

The coastal city of Qingdao also predicted roughly 500,000 new daily infections and the southern manufacturing city of Dongguan eyed up to 300,000.

Unofficial surveys and modelling based on search engine terms suggest that the wave may have already peaked in some major cities like Beijing and Chongqing.

A poll of over 150,000 residents of the southwestern province of Sichuan organized by disease control officials showed that 63% had tested positive for COVID, and estimated that infections peaked Friday.

Only six COVID deaths have been officially reported since Beijing unwound most of its restrictions earlier this month.

But crematorium workers interviewed by AFP have reported an unusually high influx of bodies, while hospitals have said they are tallying multiple fatalities per day, as emergency wards fill up.

The main funeral service center in the southern metropolis of Guangzhou postponed all ceremonies until January 10 to focus on cremations due to the “large workload,” according to a notice published online Sunday.

China’s censors and mouthpieces have been working overtime to spin the decision to scrap strict travel curbs, quarantines and snap lockdowns as a victory, even as cases soar.

 

 

Source: Voice of America

 

Long COVID: Could Mono Virus or Fat Cells Be Playing Roles?

A British historian, an Italian archaeologist and an American preschool teacher have never met in person, but they share a prominent pandemic bond.

Plagued by eerily similar symptoms, the three women are credited with describing, naming and helping bring long COVID into the public’s consciousness in early 2020.

Rachel Pope, of Liverpool, took to Twitter in late March 2020 to describe her bedeviling symptoms, then unnamed, after a coronavirus infection. Elisa Perego in Italy first used the term “long COVID,” in a May tweet that year. Amy Watson in Portland, Oregon, got inspiration in naming her Facebook support group from the trucker cap she’d been wearing, and “long hauler” soon became part of the pandemic lexicon.

Nearly three years into the pandemic, scientists are still trying to figure out why some people get long COVID and why a small portion — including the three women — have lasting symptoms.

Millions of people worldwide have had long COVID, reporting various symptoms including fatigue, lung problems, and brain fog and other neurological symptoms. Evidence suggests most recover substantially within a year, but recent data show that it has contributed to more than 3,500 U.S. deaths.

Here’s some of the latest evidence:

Women more at risk?

Many studies and anecdotal evidence suggest that women are more likely than men to develop long COVID.

There could be biological reasons.

Women’s immune systems generally mount stronger reactions to viruses, bacteria, parasites and other germs, noted Sabra Klein, a Johns Hopkins professor who studies immunity.

Women are also much more likely than men to have autoimmune diseases, where the body mistakenly attacks its own healthy cells. Some scientists believe long COVID could result from an autoimmune response triggered by the virus.

Women’s bodies also tend to have more fat tissue and emerging research suggests the coronavirus may hide in fat after infection. Scientists also are studying whether women’s fluctuating hormone levels may increase the risks.

Another possible factor: Women are more likely than men to seek health care and often more attuned to changes in their bodies, Klein noted.

“I don’t think we should ignore that,” she said. Biology and behavior are probably both at play, Klein said.

It may thus be no coincidence that it was three women who helped shine the first light on long COVID.

Pope, 46, started chronicling what she was experiencing in March 2020: flu-like symptoms, then her lungs, heart and joints were affected. After a month she started having some “OK” days, but symptoms persisted.

She and some similarly ill colleagues connected with Perego on Twitter. “We started sort of coming together because it was literally the only place where we could do that,” Pope said. “In 2020, we would joke that we’d get together for Christmas and have a party,” Pope said. “Then obviously it went on, and I think we stopped joking.”

Watson started her virtual long haulers group that April. The others soon learned of that nickname and embraced it.

Mono virus

Several studies suggest the ubiquitous Epstein-Barr virus could play a role in some cases of long COVID.

Inflammation caused by coronavirus infection can activate herpes viruses, which remain in the body after causing an acute infection, said Dr. Timothy Henrich, a virus expert at the University of California, San Francisco.

Epstein-Barr virus is among the most common of these herpes viruses: An estimated 90% of the U.S. population has been infected with it. The virus can cause mononucleosis or symptoms that may be dismissed as a cold.

Henrich is among researchers who have found immune markers signaling Epstein-Barr reactivation in the blood of long COVID patients, particularly those with fatigue.

Not all long COVID patients have these markers. But it’s possible that Epstein-Barr is causing symptoms in those who do, although scientists say more study is needed.

Some scientists also believe that Epstein-Barr triggers chronic fatigue syndrome, a condition that bears many similarities to long COVID, but that also is unproven.

Obesity

Obesity is a risk factor for severe COVID-19 infections and scientists are trying to understand why.

Stanford University researchers are among those who have found evidence that the coronavirus can infect fat cells. In a recent study, they found the virus and signs of inflammation in fat tissue taken from people who had died from COVID.

Lab tests showed that the virus can reproduce in fat tissue. That raises the possibility that fat tissue could serve as a “reservoir,” potentially fueling long COVID.

Could removing fat tissue treat or prevent some cases of long COVID? It’s a tantalizing question, but the research is preliminary, said Dr. Catherine Blish, a Stanford infectious diseases professor and a senior author of the study.

Scientists at the University of Texas Southwestern Medical Center are studying leptin, a hormone produced by fat cells that can influence the body’s immune response and promote inflammation.

They plan to study whether injections of a manufactured antibody could reduce leptin levels — and in turn inflammation from coronavirus infections or long COVID.

“We have a good scientific basis together with some preliminary data to argue that we might be on the right track,” said Dr. Philipp Scherer.

Duration

It has been estimated that about 30% of people infected with the coronavirus will develop long COVID, based on data from earlier in the pandemic.

Most people who have lingering, recurrent or new symptoms after infection will recover after about three months. Among those with symptoms at three months, about 15% will continue to have symptoms for at least nine more months, according to a recent study in the Journal of the American Medical Association.

Figuring out who’s at risk for years-long symptoms “is such a complicated question,” said Dr. Lawrence Purpura, an infectious disease expert at Columbia University.

Those with severe infections seem to be more at risk for long COVID, although it can also affect people with mild infections. Those whose infections cause severe lung damage including scarring may experience breathlessness, coughing or fatigue for more than a year. And a smaller group of patients with mild initial COVID-19 infections may develop neurologic symptoms for more than a year, including chronic fatigue and brain fog, Purpura said.

“The majority of patients will eventually recover,” he said. “It’s important for people to know that.”

It’s small consolation for the three women who helped the world recognize long COVID.

Perego, 44, developed heart, lung and neurologic problems and remains seriously ill.

She knows that scientists have learned a lot in a short time, but she says “there is a gap” between long COVID research and medical care.

“We need to translate scientific knowledge into better treatment and policy,” she said.

Watson, approaching 50, says she has “never had any kind of recovery.” She has had severe migraines, plus digestive, nerve and foot problems. Recently she developed severe anemia.

She wishes the medical community had a more organized approach to treating long COVID. Doctors say not knowing the underlying cause or causes makes that difficult.

“I just want my life back,” Watson said, “and it’s not looking like that’s all that possible.”

 

 

Source: Voice of America

 

Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region

SHANGHAI, China, Dec. 26, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announces a new exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company, for toripalimab in the Middle East and North Africa (MENA). Under the terms of the agreement, Hikma is granted an exclusive license to develop and commercialize toripalimab injection in all its MENA markets. In addition, Junshi Biosciences will grant the right of first negotiation to Hikma for the future commercialization of three under development drugs in MENA.

Toripalimab is an innovative anti-PD-1 monoclonal antibody approved for marketing in China for six indications to date. Over thirty toripalimab clinical studies covering more than fifteen indications have been conducted globally, including in China, the United States, Southeast Asia, and Europe. Ongoing or completed pivotal clinical studies evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin, among others.

“We believe Hikma is the ideal partner for us in the MENA region. As the third largest pharmaceutical company in MENA, with a history of more than 40 years, Hikma is well established and respected and offers deep-rooted expertise, with unparalleled local knowledge. The company has also demonstrated strong commercial capabilities, particularly in areas such as oncology and biotechnology,” said Dr. Ning LI, CEO of Junshi Biosciences. “We anticipate that toripalimab could be the first marketed Chinese anti-PD-1 antibody in MENA. We look forward to working closely with Hikma to establish toripalimab’s position in the MENA markets in order to provide patients with high-quality innovative care.”

Commenting on this landmark agreement, Mazen Darwazeh, Hikma’s Executive Vice Chairman and President of MENA, said: “Anti-PD-1s have changed the way cancer is treated over the past few years but, unfortunately, patient access to these treatments in the region has been sub-optimal. Toripalimab has a compelling clinical profile with impressive efficacy and safety data, and we are thrilled to be collaborating with Junshi Biosciences to equip doctors and patients in MENA with this innovative treatment.” He added, “This agreement strengthens our biotech and oncology portfolio and enables us to increase patients’ access to PD-1s, an important milestone in delivering on our purpose of putting better health, within reach, every day.”

As part of this collaboration, Hikma is granted rights to commercialize any combination product that comprises any therapeutically active pharmaceutical agent co-formulated or co-packaged with toripalimab. Junshi Biosciences further grants Hikma the right of first negotiation to three of the company’s novel oncology molecules.

About Toripalimab

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells.

More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). Currently, there are six approved indications for toripalimab in China:

  1. unresectable or metastatic melanoma after failure of standard systemic therapy;
  2. recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;
  3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;
  4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;
  5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic ESCC;
  6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”).

The first three indications have been included in the National Reimbursement Drug List (NRDL) (2021 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma and NPC.

In the United States, the Food and Drug Administration (FDA) is reviewing the Biologics License Application (BLA) resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic NPC and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy. The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).

In Europe, marketing authorization applications (MAA) were submitted to the European Medicines Agency (EMA) and the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) in November 2022 for: 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC. In December 2022, the EMA accepted the MAA.

About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people’s lives. We’re committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. As of December 3 2021, over 700,000 patients have been treated with bamlanivimab or bamlanivimab and etesevimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. A Phase III clinical study (NCT05341609) comparing the efficacy and safety of VV116 versus nirmatrelvir/ritonavir (“PAXLOVID”) for patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19, has reached its pre-specified primary endpoint and secondary efficacy endpoint. The study results show that compared to PAXLOVID, VV116 provided patients with a shorter median time to sustained clinical recovery, while achieving statistical superiority. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8720098

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

– FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA –

– Junshi Biosciences and Coherus are actively engaged in ongoing discussions with the FDA to support the inspections and gain approval of toripalimab for patients with NPC in the U.S. as quickly as possible –

SHANGHAI, China and REDWOOD CITY, Calif., Dec. 25, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that the companies have not received an action letter from the U.S. Food and Drug Administration (FDA, the Agency) regarding the Biologics License Application (BLA) for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC) by the Prescription Drug User Fee Action (PDUFA) date of December 23, 2022.

The FDA previously communicated that an on-site inspection of Junshi Biosciences’ manufacturing facility for toripalimab is required before the Agency can approve the application; however, they were unable to conduct the inspection during the current review cycle due to the ongoing impact of COVID-19 related restrictions on travel in China. The BLA for toripalimab remains under review, and Junshi Biosciences and Coherus are engaged in ongoing discussions with the Agency about the pre-approval inspection plans.

“Although toripalimab’s BLA review process has been impacted by the COVID-19 pandemic, we believe the impact is temporary,” said Dr. Sheng Yao, Senior Vice President of Junshi Biosciences. “Together with our partner Coherus, we are working with the FDA to expedite the facility inspection so it may be conducted safely as soon as possible in order to provide NPC patients with a treatment that has been demonstrated to be safe and effective. Our production operations are well prepared for the inspection.”

“There is a significant unmet need for those living with NPC, and toripalimab has demonstrated significant and clinically meaningful improvement as recognized by the FDA’s Breakthrough Therapy Designation. Both Coherus and the FDA are highly committed to bringing toripalimab to NPC patients in the U.S. as quickly as possible,” said Theresa LaVallee, Ph.D., Coherus’ Chief Development Officer. “We are working closely and collaboratively with the FDA to schedule inspections of the manufacturing facility quickly and understand the need to ensure the safety of their inspectors. We continue to support the FDA as needed to allow for their assessment of toripalimab to be finalized.”

The FDA has granted priority review for the toripalimab BLA for use in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic NPC and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy. Recurrent or metastatic NPC is an aggressive head and neck tumor which has no FDA-approved treatment options.

About toripalimab

Toripalimab is an anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD⁠-⁠1 receptor at a unique site that minimizes opportunities for the tumor cell to evade the immune system and decreases PD-1’s expression on the T-cell as a second method of restoring the body’s immune response.

The FDA granted Breakthrough Therapy designation for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC in 2021 as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC in 2020. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (“SCLC”).

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for an anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. As of December 3, 2021, over 700,000 patients have been treated with bamlanivimab or bamlanivimab and etesevimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. A Phase III clinical study (NCT05341609) comparing the efficacy and safety of VV116 versus nirmatrelvir/ritonavir (“PAXLOVID”) for patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19, has reached its pre-specified primary endpoint and secondary efficacy endpoint. The study results show that compared to PAXLOVID, VV116 provided patients with a shorter median time to sustained clinical recovery, while achieving statistical superiority. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc.). For more information, please visit: http://junshipharma.com.

About Coherus BioSciences

Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics.

In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. The Biologics License Application for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic nasopharyngeal carcinoma is currently under review by the FDA.

Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta®, and CIMERLI™ (ranibizumab-eqrn), a biosimilar of Lucentis®, in the U.S., and expects to launch the FDA-approved Humira® biosimilar YUSIMRY™ (adalimumab-aqvh) in the U.S. in 2023.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks and uncertainties inherent in the clinical drug development process; risks relating to the COVID-19 pandemic; risks related to our existing and potential collaboration partners; risks of the drug development position of Coherus’ competitors; the risks and uncertainties of the regulatory approval process, including the speed of regulatory review, international aspects of Coherus’ business, the need to schedule inspections in China and the timing of Coherus’ regulatory filings; the risk of FDA review issues; the risk of Coherus’ execution of its change in strategy from a focus on biosimilars to a strategy using cash from its portfolio to fund an oncology franchise; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ drug candidates; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Annual Report on Form 10-Q for the quarter-ended September 30, 2022, filed with the Securities and Exchange Commission on November 8, 2022, including the section therein captioned “Risk Factors” and in other documents that Coherus files with the Securities and Exchange Commission.

UDENYCA®, CIMERLI™, and YUSIMRY™, whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners, unless otherwise noted.

Junshi Biosciences Contact Information

IR Team:
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

Coherus Biosciences Contact Information

Investors:
Marek Ciszewski, SVP Investor Relations
IR@coherus.com

Media:
Jodi Sievers, VP Corporate Communications
media@coherus.com

GlobeNewswire Distribution ID 8720041

‘Avatar’ Sequel Sails to 2nd Week Atop the Box Office

“Avatar: The Way of Water” sailed to the top of the box office in its second weekend, bringing in what studios estimate Sunday will be a strong $56 million in North America — a sign that the sequel may stay afloat into the new year and approach the massive expectations that met its release.

James Cameron’s digital extravaganza for 20th Century Studios has made $253.7 million domestically in its first 10 days of release, compared to $212.7 million in the same stretch for 2009’s first “Avatar,” which would go on to become the highest-grossing film of all time.

While Cameron’s films like the “Avatar” original and “Titanic” tend to have serious legs at the box office, sequels tend to open big and decline quickly, complicating guesses on where the film will end up. Its second-weekend drop-off from the $134 million it made in its first was not precipitous, given the way blockbusters open.

“This is James Cameron’s first $100 million opener,” said Paul Dergarabedian, senior media analyst for Comscore “For this movie to have opened that big and only dropped 58%, it shows it has staying power.”


Globally, “The Way of Water” is already the third highest-grossing film released in 2022, bringing in $855 million — putting it behind only “Top Gun: Maverick” and “Jurassic World Dominion” — and is a lock to surpass $1 billion.

It’s also clear sailing for the film looking ahead, with more holiday time coming and no comparable competition until February, when Marvel’s “Ant-Man and the Wasp: Quantumania” is released.

Storms across the U.S. could keep people home, however.

“The biggest foe that Avatar is facing at this moment is the weather,” Dergarabedian said.

Universal’s animated Shrek spinoff, “Puss in Boots: The Last Wish,” featuring the voices of Antonio Banderas and Salma Hayek, finished a distant second with $11.35 million in its opening weekend.

Sony’s biopic “Whitney Houston: I Wanna Dance With Somebody” finished third with $5.3 million.

The weekend’s biggest disappointment was “Babylon,” the epic of early Hollywood from “La La Land” director Damian Chazelle starring Brad Pitt and Margo Robbie. In a nationwide release it brought in just $3.5 million, finishing fourth.

The tepid, $6.5 million opening weekend in October of director David O. Russell’s “Amsterdam,” another film, set in a similar period, that combined prestige, scope, star power and a celebrated auteur, brought industry worries that audiences just weren’t flocking to theaters for such films.

The concerns proved justified, as “Babylon” barely made more than half of the opening of “Amsterdam.”

The coming weeks in theaters, streaming showings and any nominations it may get could help “Babylon” rise above bomb status.

“I would say Babylon is a movie that isn’t about the opening weekend,” Dergarabedian said. “We’ll have to see what it does in the coming weeks then into the new year, particularly if it gets more awards buzz.”


Estimated ticket sales for Friday through Sunday at U.S. and Canadian theaters, according to Comscore, with Wednesday through Sunday in parentheses. Final domestic figures will be released Monday.

  1. “Avatar: The Way of Water,” $56 million.
  2. “Puss in Boots: The Last Wish,” 11.35 million.
  3. “Whitney Houston: I Wanna Dance with Somebody,” $5.3 million.
  4. “Babylon,” $3.5 million.
  5. “Violent Night,” $3.14 million.
  6. “Black Panther: Wakanda Forever,” $3 million.
  7. “The Whale,” $924,000.
  8. “The Menu,” $617,000.
  9. “The Fabelmans,” $550,000.
  10. “Strange World,” $410,000.

 

 

Source: Voice of America

China’s Zhejiang Has 1 Million Daily COVID Cases, Expected to Double

China’s Zhejiang, a big industrial province near Shanghai, is battling around a million new daily COVID-19 infections, a number expected to double in the days ahead, the provincial government said Sunday.

Despite a record surge of cases nationwide, China reported no COVID deaths on the mainland for the five days through Saturday, the Chinese Center for Disease Control and Prevention said Sunday.

Citizens and experts have called for more accurate data as infections surged after Beijing made sweeping changes to a zero-COVID policy that had put hundreds of millions of its citizens under relentless lockdowns and battered the world’s second-largest economy.

Nationwide figures from China had become incomplete as the National Health Commission stopped reporting asymptomatic infections, making it harder to track cases. On Sunday the commission stopped reporting daily figures, which the China CDC then published.

Zhejiang is among the few areas to estimate their recent spikes in infections including asymptomatic cases.

“The infection peak is estimated to arrive earlier in Zhejiang and to enter a period of elevated level around New Year’s Day, during which the daily new infection number will be up to two million,” the Zhejiang government said in a statement.

Zhejiang, with a population of 65.4 million, said that among the 13,583 infections being treated in the province’s hospitals, one patient had severe symptoms caused by COVID, while 242 infections of severe and critical conditions were caused by underlying diseases.

China narrowed its definition for reporting COVID deaths, counting only those from COVID-caused pneumonia or respiratory failure, raising eyebrows among world health experts.

The World Health Organization has received no data from China on new COVID hospitalizations since Beijing eased its restrictions. The organization says the data gap might be due to the authorities struggling to tally cases in the world’s most populous country.

‘Most dangerous weeks’

“China is entering the most dangerous weeks of the pandemic,” said a research note from Capital Economics. “The authorities are making almost no efforts now to slow the spread of infections and, with the migration ahead of Lunar New Year getting started, any parts of the country not currently in a major COVID wave will be soon.”

The cities of Qingdao and Dongguan have each estimated tens of thousands of daily COVID infections recently, much higher than the national daily toll without asymptomatic cases.

The country’s health care system has been under enormous strain, with staff being asked to work while sick and even retired medical workers in rural communities being rehired to help grassroots efforts, according to state media.

Bolstering the urgency is the approach of the Lunar New Year in January, when huge numbers of people return home.

Visits to Zhejiang fever clinics hit 408,400 a day — 14 times normal levels — in the past week, a Zhejiang official told a news conference.

Daily requests to the emergency center in Zhejiang’s capital, Hangzhou, have recently more than tripled on average from last year’s level, state television reported Sunday, citing a Hangzhou health official.

The eastern city of Suzhou said late Saturday its emergency line received a record 7,233 calls Thursday.

 

Source: Voice of America